Instead of following the traditional path of drug development, AI is attempting to rewrite a new chapter in the development of medicine, but now it has to prove it, with AI technology and data bringing about fundamental changes, and AI algorithms rewriting drug development. ...read more

According to the EvaluatePharma 2025 report, annual sales of GLP-1 drugs will account for 9% of the overall global prescription drug market, suggesting that the treatment of diabetes and weight management will be a key factor in the development of the GLP-1 class. ...read more

AI landing everywhere, CES 2026 emphasized that AI has been immersed in life innovation (DIVE IN) from last year's technological innovation, and further towards agentic AI (agentic). ...read more

Contactless health technology is on the rise, taking over all aspects of home biometrics checkups

As shown in Figure 2, this CES live demonstration of contactless health ...read more

[2026 Biomedical and Healthcare Industry Executive Summary

From an industrial economic point of view, the development of the biotechnology and medical health industry in 2026 ...read more

[Drugs]
1. GLP-1 weight-loss drug is sold worldwide, and the battle for the new force starts again.
Annual sales of GLP-1 drugs will account for ...read more

Medical Device Equipment]

1. Smart wearable devices are evolving from a technological trend to a universal standard, and are becoming the number one thing in the world. ...read more

Emerging Therapies

1. Regenerative medicine opens AI-enabled gene editing + in vivo gene editing (In vivo) ...read more

Commentator: Shin Chung-chul, Director of Health Center, Ji-Pu Industrial Trend Research Institute

Lancet confirms that obesity and diabetes significantly accelerate the development of metabolic steatohepatitis. ...read more